| Date | Time | Source | Headline | Symbol | Company |
| 07/10/2006 | 3:14PM | PR Newswire (US) | Forest Laboratories, Inc. Sets Date and Conference Call For Fiscal 2007 First Quarter Earnings | NYSE:FRX | Forest Road Acquisition Corp |
| 05/18/2006 | 4:02PM | PR Newswire (US) | /C O R R E C T I O N -- Forest Laboratories, Inc./ | NYSE:FRX | Forest Road Acquisition Corp |
| 05/18/2006 | 3:26PM | PR Newswire (US) | Forest Laboratories Announces Nesli Basgoz, M.D. Named to Board of Directors | NYSE:FRX | Forest Road Acquisition Corp |
| 05/18/2006 | 3:25PM | PR Newswire (US) | Forest Laboratories, Inc. Announces New Share Repurchase Program | NYSE:FRX | Forest Road Acquisition Corp |
| 04/25/2006 | 12:18PM | PR Newswire (US) | Seven Summits Research Releases Comments on OXY, FRX, WHR, COH, and BNI | NYSE:FRX | Forest Road Acquisition Corp |
| 04/25/2006 | 9:07AM | PR Newswire (US) | Forest Laboratories, Inc. Reports Q4'06 Diluted Earnings Per Share of $0.28 Including $0.37 Per Share Charge for Licensing and | NYSE:FRX | Forest Road Acquisition Corp |
| 04/12/2006 | 5:05PM | PR Newswire (US) | Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2006 Fourth Quarter Earnings | NYSE:FRX | Forest Road Acquisition Corp |
| 04/10/2006 | 9:00AM | PR Newswire (US) | Forest and Almirall Announce a Development and Marketing Collaboration Agreement on New Therapy for COPD | NYSE:FRX | Forest Road Acquisition Corp |
| 03/02/2006 | 8:30AM | PR Newswire (US) | Forest Laboratories Receives Patent Term Extension for Lexapro | NYSE:FRX | Forest Road Acquisition Corp |
| 02/23/2006 | 8:35AM | PR Newswire (US) | Replidyne and Forest Laboratories Announce FDA Acceptance for Review of New Drug Application for Oral Antibiotic Faropenem Medox | NYSE:FRX | Forest Road Acquisition Corp |
| 02/15/2006 | 6:07PM | PR Newswire (US) | /C O R R E C T I O N -- Forest Laboratories, Inc./ | NYSE:FRX | |
| 02/15/2006 | 4:05PM | PR Newswire (US) | Forest Laboratories Revises Research and Development Spending Projection to Account for Upfront Payments for Two Recent In-Licen | NYSE:FRX | Forest Road Acquisition Corp |
| 02/13/2006 | 8:20AM | PR Newswire (US) | Replidyne and Forest Laboratories Announce Faropenem Medoxomil Licensing Agreement | NYSE:FRX | Forest Road Acquisition Corp |
| 01/17/2006 | 8:09AM | PR Newswire (US) | Forest Laboratories, Inc. Reports Q3'06 Diluted Earnings Per Share of $0.57 Including $0.05 Per Share Licensing Payment | NYSE:FRX | Forest Road Acquisition Corp |
| 01/11/2006 | 6:15PM | PR Newswire (US) | Mylan Laboratories and Forest Laboratories Announce Nebivolol Licensing Agreement | NYSE:FRX | Forest Road Acquisition Corp |
| 01/05/2006 | 8:12AM | PR Newswire (US) | Forest Laboratories, Inc. and Cypress Bioscience, Inc. to Commence Third Milnacipran Phase III Trial | NYSE:FRX | Forest Road Acquisition Corp |
| 01/04/2006 | 12:38PM | PR Newswire (US) | Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2006 Third Quarter Earnings | NYSE:FRX | Forest Road Acquisition Corp |
| 11/28/2005 | 4:10PM | PR Newswire (US) | Gedeon Richter and Forest Laboratories Expand Relationship with Two New Collaborations for CNS Compounds | NYSE:FRX | Forest Road Acquisition Corp |
| 10/26/2005 | 5:10PM | PR Newswire (US) | Forest Laboratories and H. Lundbeck A/S Announce Lexapro Patent Litigation Trial Date Rescheduled to March 15, 2006 | NYSE:FRX | Forest Road Acquisition Corp |
| 10/18/2005 | 10:44AM | PR Newswire (US) | MORNING UPDATE: Seven Summits Research issues alerts for IBM, WFC, GENZ, FRX, and NVS | NYSE:FRX | Forest Road Acquisition Corp |
| 10/18/2005 | 9:15AM | PR Newswire (US) | Forest Laboratories Announces Executives Intend to Exercise Options With Intent to Hold Shares | NYSE:FRX | Forest Road Acquisition Corp |
| 10/18/2005 | 9:12AM | PR Newswire (US) | Forest Laboratories Reports Earnings Per Share of $0.59 for Q2'06 | NYSE:FRX | Forest Road Acquisition Corp |
| 10/06/2005 | 9:01AM | PR Newswire (US) | Forest Laboratories and Lundbeck Enter Into Settlement Agreement With Alphapharm Related to Lexapro Patent Litigation | NYSE:FRX | Forest Road Acquisition Corp |
| 10/05/2005 | 5:06PM | PR Newswire (US) | Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2006 Second Quarter Earnings | NYSE:FRX | Forest Road Acquisition Corp |
| 09/28/2005 | 9:10PM | PR Newswire (US) | /C O R R E C T I O N -- Forest Laboratories, Inc.; Cypress Biosciences, Inc./ | NYSE:FRX | Forest Road Acquisition Corp |
| 09/28/2005 | 5:51PM | PR Newswire (US) | Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Results of Phase III Study for Milnacipran as a Treatment for Fi | NYSE:FRX | Forest Road Acquisition Corp |
| 08/26/2005 | 1:00PM | PR Newswire (US) | Forest Laboratories Updates Lexapro Patent Litigation Status | NYSE:FRX | Forest Road Acquisition Corp |
| 08/18/2005 | 6:10PM | PR Newswire (US) | Oral Solution Formulation of Namenda(R), the Only FDA-Approved Oral Solution for Moderate to Severe Alzheimer's Disease, Now Ava | NYSE:FRX | Forest Road Acquisition Corp |
| 07/25/2005 | 1:31PM | PR Newswire (US) | Forest Laboratories Announces FDA Decision on Supplemental New Drug Application for Namenda(R) | NYSE:FRX | Forest Road Acquisition Corp |
| 07/20/2005 | 11:15AM | PR Newswire (US) | MORNING UPDATE: Mankus-Lavelle Group issues alerts for MOT, JNPR, MO, MEL, and FRX | NYSE:FRX | Forest Road Acquisition Corp |